(2006) Journal of Immunology n=20 Preclinical research showing ipamorelin augmented T-cell and B-cell immune responses
If a patient starts on semaglutide and plateaus, their physician can evaluate whether switching to tirzepatide makes sense
The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
In Boyden chamber assays, TB4 stimulated keratinocyte migration 23-fold over medium alone within 45 hours with as little as 10 pg sufficient to produce a potent stimulatory response
Some researchers alternate between the two, using AHK-Cu one week and GHK-Cu the next